Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Kater, AP, Seymour, JF, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (12 more authors) (2019) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 34 (4). pp. 269-277. ISSN 0732-183X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 by American Society of Clinical Oncology. Reproduced in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 1 February 2019
  • Accepted: 13 November 2018
  • Published (online): 3 December 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 08 Jan 2019 16:29
Last Modified: 03 Jun 2019 00:43
Status: Published
Publisher: American Society of Clinical Oncology
Identification Number: https://doi.org/10.1200/jco.18.01580
Related URLs:

Share / Export

Statistics